Skip to content

Nosocomial COVID-19 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021

Proportion of Nosocomial COVID-19 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05567874
Acronym
COVIDIN
Enrollment
216
Registered
2022-10-05
Start date
2022-01-03
Completion date
2022-08-31
Last updated
2023-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS CoV 2 Infection

Brief summary

The rate of nosocomial SARS-CoV2 infections found in the different studies since the beginning of the pandemic is very variable (\<1% in hospitals in the USA to about 20% in a British hospital). Mortality related to these nosocomial SARS-CoV2 infections is higher than in the general population. The risk factors identified for this nosocomial acquisition are multiple. We were confronted with nosocomial acquisitions and cluster situations in the services, without exhaustive data to measure these phenomena, and we lacked data to consider areas for improvement. The objectives of this study are to determine the proportion of nosocomial SARS COV 2 infections in the total number of patients hospitalized with a Covid-19 infection at the CHR Metz-Thionville in 2021, and to describe the characteristics of this population.

Interventions

OTHERNosocomial SARS-COV 2 Infection proportion

Proportion of Nosocomial SARS-COV 2 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021

Sponsors

Centre Hospitalier Régional Metz-Thionville
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients hospitalised at the CHR Metz-Thionville in medicine, surgery and obstetrics (MCO) or geriatric follow-up and rehabilitation care (SSR) units, in 2021 for a Covid-19 infection defined by the existence of a positive PCR result for SARS-CoV2 during the stay, or by the existence of an ICD10 code for COVID in the PMSI data of the health care establishment

Exclusion criteria

* Opposition to participate in the study after reading the patient information note.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of hospital-acquired infections in patients hospitalised with a covid-19 infectionup to 8 months after the third COVID-19 waveSeveral elements are taken into account: a) the time between entry into the establishment and the first positive SARS COV 2 PCR, b) the time between entry into the establishment and the appearance of the most frequent symptoms (fever, cough), if present in the patient, in the seven days preceding the first positive SARS COV 2 PCR, c) the existence of an epidemiological link with other infected patients, via contact in a double room with another case, and/or via hospitalisation in a department concerned by a cluster situation according to the Santé Publique France definition of May 2020 (identified on the basis of monitoring and surveillance data from the hygiene department).

Secondary

MeasureTime frameDescription
Description of the nosocomial infected populationup to 8 months after the third COVID-19 waveage, sex, hospital unit care, outcomes of stay, vaccination status, associated conditions (comorbidities according to Charlson score, obesity, pregnancy), existence of screening on admission, time to acquisition of nosocomial infection, number of negative SARS-COV 2 PCRs in the institution before the first positive PCR, type of variant, presence of symptoms (cough, fever), stay in a double room in the 14 days prior to infection, cluster status in the ward, length of stay after infection.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026